|
|
Vaccine Detail
|
Bcr-Abl (b2a2)-Derived Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: Bcr-Abl (b2a2)-Derived Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: bcr-abl b2a2 fusion oncoprotein (NCIT_C61309)
- Immunization Route: subcutaneous injection
- Description: This is a peptide vaccine consisting of the bcr-abl b2a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b2a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b2a2 fusion protein. (NCIT_C61309) The vaccine is made from made from the proteins that cause leukemia cells in CML to behave abnormally. Imatinib mesylate is the standard therapy for CML and blocks the function of this protein. In combination, these may decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease. (NCT00267085)
|
| Host Response |
|
|
| References |
NCIT_C61309: Bcr-Abl (b2a2)-Derived Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C61309]
NCT00267085: Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease [https://clinicaltrials.gov/study/NCT00267085]
|
|
